Chargement en cours...
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with...
Enregistré dans:
| Publié dans: | Clin Mol Hepatol |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Korean Association for the Study of the Liver
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4612290/ https://ncbi.nlm.nih.gov/pubmed/26527250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2015.21.3.287 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|